We believe that to concretely help patients, we need not only a traditional and pharmacological commitment but also a social and educational one
In Conversation
Egypt is a place where it takes longer to do business, there are hurdles because we have a huge administration and bureaucracy, but it is worth…
Even though we are a mid-sized company, and the competition is tough, we are working very hard to achieve success [in oncology]
UCB has a firm commitment to innovation as evidenced by the fact that it invests 28% of its turnover in R&D.
[In the National Recovery and Resilience Plan] AGENAS is ... the point of connection between the Ministry of Health and the regions [and] EUR 15.63 billion…
Since the Organon spinoff, the strategy to focus on specific parts of the portfolio is clearer than ever. We are fully committed to working on three…
... price erosion is such a big concern in the Spanish market ... The pricing system for generics is forcing both brands and generics to compete…
We are one of the few companies focusing heavily on pain. There are not many ... because is not an easy area in which to bring…
... the difference between IBSA and other companies is that we have both pharma and medical devices ... We develop and patent new technologies to deliver…
... the decision to combine our capabilities in the US allowed Stevanato Group to reach an agreement with the Biomedical Advanced Research and Development Authority (BARDA)…
... the needs of our customers go way beyond catheters, stents or artificial pacemakers; we try to go alongside them through their particular journey with patients.
Our mission is focused on providing support to the pharmaceutical and biomedical industries from the beginning of a project to its completion, in reducing the timeline…
